Journey Medical Corporation Common Stock DERM

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

• Zacks Investment Research 21 sept

  Are Options Traders Betting on a Big Move in Journey Medical Stock?

  Journey Medical (DERM) is experiencing elevated implied volatility in its September 2026 $50 call options, suggesting traders expect significant price movement. However, the company holds a Zacks Rank #4 (Sell) rating, with analysts downgrading estimates over the past 60 days, reducing consensus earnings from 9 cents to 2 cents per share. The high volatility may present opportunities for premium-selling strategies rather than bullish positioning.

  

• GlobeNewswire Inc. 31 ago

  Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories

  The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.